Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
, , e | 18 giu 2022
INFORMAZIONI SU QUESTO ARTICOLO
Article Category: Short Communication
Pubblicato online: 18 giu 2022
Pagine: 84 - 86
Ricevuto: 25 apr 2022
Accettato: 10 mag 2022
DOI: https://doi.org/10.2478/afpuc-2022-0006
Parole chiave
© 2022 Jan Juřica et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Overview of ICIs and their indications - number of patients treated in the Masaryk Memorial Cancer Institute over the years 2011–2021.
| Nivolumab | 130 | 97 | 44 | 15 | 9 | 6 | 15 | 316 |
| Pembrolizumab | 18 | 9 | 43 | 2 | 2 | 4 | 15 | 93 |
| Ipilimumab | 67 | 1 | 0 | 68 | ||||
| Nivolumab + Ipilimumab | 16 | 20 | 9 | 11 | 9 | 65 | ||
| Atezolizumab | 7 | 12 | 7 | 3 | 15 | 44 | ||
| Spartalizumab | 4 | 5 | 2 | 3 | 5 | 19 | ||
| Durvalumab | 11 | 4 | 1 | 16 | ||||
| Avelumab | 6 | 1 | 1 | 1 | 2 | 3 | 14 | |
| Cemiplimab | 8 | 8 | ||||||
| Nivolumab + Relatlimab | 4 | 1 | 5 | |||||
| 235 | 144 | 114 | 37 | 27 | 19 | 72 | 648 |
Overview of the frequency of serious irAEs of ICIs in the Masaryk Memorial Cancer Institute.
| Nivolumab | 316 | 33 | 10.4 |
| Pembrolizumab | 93 | 11 | 11.8 |
| Ipilimumab | 68 | 11 | 16.2 |
| Nivolumab + Ipilimumab | 65 | 20 | 30.8 |
| Atezolizumab | 44 | 3 | 6.8 |
| Spartalizumab | 19 | 1 | 5.3 |
| Durvalumab | 16 | 2 | 12.5 |
| Nivolumab + Relatlimab | 5 | 2 | 40.0 |
| 648 | 83 | 12.8 |